Publications by authors named "J Bockmann"
Article Synopsis
- Bulevirtide (BLV) is a new treatment approved in Europe for hepatitis D virus (HDV) infections, and this study examines its effectiveness using paired liver biopsies taken before and after treatment.
- The results showed significant reductions in intrahepatic HDV RNA levels after 24 and 48 weeks of BLV treatment, alongside decreases in liver inflammation markers.
- The study suggests that by blocking virus entry, BLV may reduce liver damage and potentially lead to a cure for some patients with long-term use.
The Shank3 gene encodes the major postsynaptic scaffolding protein SHANK3. Its mutation causes a syndromic form of autism spectrum disorder (ASD): Phelan-McDermid Syndrome (PMDS). It is characterized by global developmental delay, intellectual disorders (ID), ASD behavior, affective symptoms, as well as extra-cerebral symptoms.
View Article and Find Full Text PDFPhelan-McDermid syndrome (PMS) is a syndromic form of Autism Spectrum Disorders (ASD) classified as a rare genetic neurodevelopmental disorder featuring global developmental delay, absent or delayed speech, ASD-like behaviour and neonatal skeletal muscle hypotonia. PMS is caused by a heterozygous deletion of the distal end of chromosome 22q13.3 or mutations.
View Article and Find Full Text PDFArticle Synopsis
- Hepatitis D virus (HDV) is linked to severe viral hepatitis and this study investigates antibody levels in 40 chronic hepatitis D (CHD) patients compared to 70 chronic hepatitis B (CHB) patients.
- The study found that CHD patients have significantly higher non-disease-specific antibody (NOSA) titers and immunoglobulin G (IgG) levels than CHB patients, with CHD showing 69% and 16.9 g/L respectively.
- Autoantibodies in CHD patients are common but have unclear clinical implications, and their IgG levels correlate with higher viral loads and liver damage indicators, regardless of prior treatment with pegylated interferon-α.
Background & Aims: Pegylated interferon alpha (pegIFNα) is commonly used for the treatment of people infected with HDV. However, its mode of action in HDV-infected cells remains elusive and only a minority of people respond to pegIFNα therapy. Herein, we aimed to assess the responsiveness of three different cloned HDV strains to pegIFNα We used a previously cloned HDV genotype 1 strain (dubbed HDV-1a) that appeared insensitive to interferon-α , a new HDV strain (HDV-1p) we isolated from an individual achieving later sustained response to IFNα therapy, and one phylogenetically distant genotype 3 strain (HDV-3).
View Article and Find Full Text PDF